Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| monoclonal antibodies | 5862 | 2382896-07-1 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Voyxact contains sibeprenlimab-szsi, an A Proliferation Inducing Ligand (APRIL) blocker and humanized immunoglobulin G2 (IgG2) monoclonal antibody produced by Chinese Hamster Ovary (CHO) cells. Sibeprenlimab binds to APRIL with a dissociation constant (KD) of 0.95 pM, which blocks signaling at the B cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptors. Inhibition of APRIL results in reduced levels of serum galactose-deficient immunoglobulin A1 (Gd-IgA1), which is implicated in the pathogenesis of IgAN.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 25, 2025 | FDA | Otsuka Pharmaceutical Company, Ltd |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | L04AG18 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Monoclonal antibodies |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Primary immunoglobulin A nephropathy | indication | 68779003 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Tumor necrosis factor ligand superfamily member 13 | Cytokine | ANTIBODY BINDING | Kd | 12.02 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| 4044443 | VANDF |
| 4044444 | VANDF |
| C6056380 | UMLSCUI |
| CHEMBL4594614 | ChEMBL_ID |
| 12102 | IUPHAR_LIGAND_ID |
| 11575 | INN_ID |
| 2728380 | RXNORM |
| C000731962 | MESH_SUPPLEMENTAL_RECORD_UI |
| D12374 | KEGG_DRUG |
| GHX28QZ7DD | UNII |
| 44538 | MMSL |
| d10342 | MMSL |
| 020298 | NDDF |
| CHEBI:758086 | CHEBI |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| VOYXACT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59148-400 | INJECTION | 200 mg | SUBCUTANEOUS | BLA | 28 sections |